WARRINGTON, Pa., April 14, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it continues to make significant progress in the development of its proprietary Capillary Aerosolization Technology. Since obtaining exclusive development rights in June 2008, Discovery Labs has successfully advanced the fundamental design, improving the reliability and performance of the capillary aerosol generating systems. The Capillary Aerosolization Technology is designed to produce a consistent, high capacity aerosol with a defined particle size, intended to deliver aerosolized KL4 surfactant to the deep lung. Discovery Labs believes that its novel Capillary Aerosolization Technology will support delivery of surfactant therapy without the risk associated with invasive endotracheal intubation and mechanical ventilation, potentially addressing a broad range of respiratory disorders associated with surfactant dysfunction for which current treatment options are limited.
